Search results
Results from the WOW.Com Content Network
Lifileucel, sold under the brand name Amtagvi, is an adoptive T cell therapy used for the treatment of melanoma. [1] [2] [3] Specifically, lifileucel is a tumor-derived T cell immunotherapy composed of a recipient's own T cells. A portion of the recipient's tumor tissue is removed during a surgical procedure prior to treatment. [3]
2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) in July. This was the third new approval since 2021. Read On The Fox ...
Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID) Talimogene laherparepvec (Imlygic): treatment for melanoma in patients who have recurring skin lesions [17] Tisagenlecleucel (Kymriah): treatment for B cell lymphoblastic leukemia [18] Valoctocogene roxaparvovec (Roctavian): treatment for hemophilia A [19] [20] [21] Voretigene ...
Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved ...
In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company, and Eisai, a pharmaceutical ...
A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. [1] The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.
Iovance Biotherapeutics said on Friday the U.S. health regulator has granted an accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be ...
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...